These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 25156567)

  • 1. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.
    Franco J; Witkiewicz AK; Knudsen ES
    Oncotarget; 2014 Aug; 5(15):6512-25. PubMed ID: 25156567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
    Witkiewicz AK; Borja NA; Franco J; Brody JR; Yeo CJ; Mansour J; Choti MA; McCue P; Knudsen ES
    Oncotarget; 2015 Jun; 6(18):15788-801. PubMed ID: 26158861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.
    Salvador-Barbero B; Álvarez-Fernández M; Zapatero-Solana E; El Bakkali A; Menéndez MDC; López-Casas PP; Di Domenico T; Xie T; VanArsdale T; Shields DJ; Hidalgo M; Malumbres M
    Cancer Cell; 2020 Mar; 37(3):340-353.e6. PubMed ID: 32109375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.
    Franco J; Balaji U; Freinkman E; Witkiewicz AK; Knudsen ES
    Cell Rep; 2016 Feb; 14(5):979-990. PubMed ID: 26804906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer.
    Knudsen ES; Kumarasamy V; Ruiz A; Sivinski J; Chung S; Grant A; Vail P; Chauhan SS; Jie T; Riall TS; Witkiewicz AK
    Oncogene; 2019 May; 38(18):3355-3370. PubMed ID: 30696953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma.
    Zhang B; Li D; Jin X; Zhang K
    Int J Biochem Cell Biol; 2020 Nov; 128():105859. PubMed ID: 32987196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
    Knudsen ES; Witkiewicz AK
    Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.
    Chou A; Froio D; Nagrial AM; Parkin A; Murphy KJ; Chin VT; Wohl D; Steinmann A; Stark R; Drury A; Walters SN; Vennin C; Burgess A; Pinese M; Chantrill LA; Cowley MJ; Molloy TJ; ; Waddell N; Johns A; Grimmond SM; Chang DK; Biankin AV; Sansom OJ; Morton JP; Grey ST; Cox TR; Turchini J; Samra J; Clarke SJ; Timpson P; Gill AJ; Pajic M
    Gut; 2018 Dec; 67(12):2142-2155. PubMed ID: 29080858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
    Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
    Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.
    Maust JD; Frankowski-McGregor CL; Bankhead A; Simeone DM; Sebolt-Leopold JS
    Mol Cancer Ther; 2018 Dec; 17(12):2495-2506. PubMed ID: 30254182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
    Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
    Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
    Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
    Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
    Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
    Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
    Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
    Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
    Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
    [No Abstract]   [Full Text] [Related]  

  • 17. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells.
    Liu F; Korc M
    Mol Cancer Ther; 2012 Oct; 11(10):2138-48. PubMed ID: 22869556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.
    Kumarasamy V; Ruiz A; Nambiar R; Witkiewicz AK; Knudsen ES
    Oncogene; 2020 Feb; 39(9):1831-1845. PubMed ID: 31745297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.